BIRC5 and acute lymphoblastic leukemia: In a study published in 2012 that included lymphoblastic leukemia patients, Tyner et al.,(28) observed that sepantronium bromide (YM-155) was able to inhibit survivin action, thus reducing lymphoblast activity.